Minimally-Invasive Replacement of Mitral Valve for Mitral Regurgitation - European Reimbursement Report

  • ID: 4243320
  • Report
  • Region: Europe
  • European Med Tech Reimbursement Consulting AB
1 of 4
Essential Information About Reimbursement and National Funding of the Minimally-Invasive Replacement of Mitral Valve for Mitral Regurgitation

This report presents summary of the reimbursement situation for a minimally-invasive (transapical via mini-thoracotomy) replacement of mitral valve for mitral regurgitation.

Report includes essential information about reimbursement and national funding of the minimally-invasive replacement of mitral valve for mitral regurgitation, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland
Note: Product cover images may vary from those shown
2 of 4

1. Introduction and summary

2. Executive summary table

3. Contents

4. Methodology

5. Reimbursement analysis in Austria
5.1. Overview of the reimbursement system
5.2. Reimbursement for minimally invasive replacement of mitral valve
5.2.1. Procedure coding
5.2.2. Diagnosis coding
5.2.3. Payment mechanism and reimbursement tariffs
5.2.4. Health technology assessment by LBI-HTA

6. Reimbursement analysis in Belgium
6.1. Overview of the reimbursement system
6.2. Reimbursement for minimally invasive replacement of mitral valve

7. Reimbursement analysis in Denmark
7.1. Overview of the reimbursement system
7.2. Reimbursement for minimally invasive replacement of mitral valve
7.2.1. Procedure coding
7.2.2. Diagnosis coding
7.2.3. Payment mechanism and reimbursement tariffs

8. Reimbursement analysis in England
8.1. Overview of the reimbursement system
8.2. Reimbursement for minimally invasive replacement of mitral valve
8.2.1. Procedure coding
8.2.2. Diagnosis coding
8.2.3. Payment mechanism and reimbursement tariffs
8.2.4. Policy considerations
8.2.4.1. National commissioning by NHS England
8.2.4.2. Health technology assessment by NICE

9. Reimbursement analysis in France
9.1. Overview of the reimbursement system
9.2. Reimbursement for minimally invasive replacement of mitral valve

10. Reimbursement analysis in Germany
10.1. Overview of the reimbursement system
10.2. Reimbursement for minimally invasive replacement of mitral valve
10.2.1. Procedure coding
10.2.2. Diagnosis coding
10.2.3. Payment mechanism and reimbursement tariffs
10.2.4. Policy considerations

11. Reimbursement analysis in Italy
11.1. Overview of the reimbursement system
11.2. Reimbursement for minimally invasive replacement of mitral valve
11.2.1. Procedure coding at national level
11.2.2. Procedure coding at regional level (Emilia-Romagna region)
11.2.3. Diagnosis coding
11.2.4. Payment mechanism and reimbursement tariffs at national level
11.2.5. Payment mechanism and reimbursement tariffs at regional level

12. Reimbursement analysis in the Netherlands
12.1. Overview of the reimbursement system
12.2. Reimbursement for minimally invasive replacement of mitral valve
12.2.1. Procedure coding
12.2.2. Material coding
12.2.3. Diagnosis coding
12.2.4. Payment mechanism and reimbursement tariffs
12.2.5. Policy considerations
12.2.6. Health technology assessment by National Healthcare Institute

13. Reimbursement analysis in Norway
13.1. Overview of the reimbursement system
13.2. Reimbursement for minimally invasive replacement of mitral valve
13.2.1. Policy considerations

14. Reimbursement analysis in Sweden
14.1. Overview of the reimbursement system
14.2. Reimbursement for minimally invasive replacement of mitral valve
14.2.1. Procedure coding
14.2.2. Diagnosis coding
14.2.3. Payment mechanism and reimbursement tariffs

15. Reimbursement analysis in Switzerland
15.1. Overview of the reimbursement system
15.2. Reimbursement for minimally invasive replacement of mitral valve
15.2.1. Procedure coding
15.2.2. Diagnosis coding
15.2.3. Payment mechanism and reimbursement tariffs

16. Disclaimer

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Vascular (Tendyne valve)
  • Cephea
  • Edwards Lifesciences (SAPIEN XT valve, CardiAQ-Edwards Transcatheter Mitral Valve, Fortis transcatheter mitral valve)
  • Micro Interventional Devices (Permavalve)
  • NaviGate Cardiac Structures (NAVI System)
  • Neovasc (Tiara device)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll